Does Affinity Health Plan Cover Adderall?

Understanding Affinity Health Plan and Its Current Status

Affinity Health Plan was a nonprofit Medicaid managed care organization that served members across New York City's five boroughs. In 2014, Molina Healthcare acquired Affinity, integrating its roughly 260,000 members into Molina Healthcare of New York [1]. If you still carry a card that says "Affinity Health Plan," your coverage now operates under Molina Healthcare's formulary and benefits structure.

Why the Name Still Circulates

Many members and providers continue to reference Affinity Health Plan in conversation and online searches. Molina maintained some Affinity branding during the transition period, and older provider directories still list the name. For prescription drug questions, you should contact Molina Healthcare of New York directly or check the current Molina formulary.

What This Means for Your Adderall Coverage

Because Molina absorbed Affinity's member base, the drug formulary that governs your Adderall coverage is Molina Healthcare of New York's Medicaid Preferred Drug List (PDL). New York State's Medicaid program publishes a standardized PDL that all managed care organizations, including Molina, must follow as a baseline [2]. Individual plans can add drugs to their formularies but cannot remove medications that appear on the state PDL without offering a clinically appropriate alternative.

Adderall Formulary Status Under Medicaid Managed Care

Generic Adderall (mixed amphetamine salts, immediate-release) is classified as a preferred stimulant on most New York Medicaid formularies. This means it sits on the lowest cost-sharing tier and does not require prior authorization for standard doses in patients with a documented ADHD diagnosis [2].

Generic IR vs. Brand and XR Formulations

The formulary distinction between formulations matters. Generic mixed amphetamine salts IR (immediate-release) tablets are available in 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg, 20 mg, and 30 mg strengths. These generics entered the market after Teva Pharmaceutical received FDA approval for its abbreviated new drug application, and multiple manufacturers now produce them [3].

Brand-name Adderall is rarely dispensed today because the generic is therapeutically equivalent (rated AB by the FDA). Adderall XR (extended-release capsules) occupies a different formulary position. Generic extended-release mixed amphetamine salts may be covered but often sit on a non-preferred tier, requiring the prescriber to submit prior authorization documentation showing that the immediate-release formulation was tried first or is clinically inappropriate [4].

Step Therapy Requirements

New York Medicaid managed care plans commonly impose step therapy for ADHD stimulants. A typical step therapy protocol looks like this:

1. Step 1: Trial of a preferred generic stimulant (e.g., generic mixed amphetamine salts IR or generic methylphenidate IR)
2. Step 2: If Step 1 fails or produces intolerable side effects, the prescriber requests prior authorization for a non-preferred agent (e.g., Adderall XR, Vyvanse, or Mydayis)

The American Academy of Pediatrics (AAP) 2019 clinical practice guideline for ADHD recommends stimulant medications as first-line pharmacotherapy for children aged 6 and older, adolescents, and adults, without specifying a preference for IR over XR formulations [5]. If your clinician believes the extended-release formulation is medically necessary from the start, they can submit a clinical rationale to bypass step therapy.

Prior Authorization: When It Applies and How It Works

Prior authorization (PA) is a utilization management tool that requires your prescriber to obtain approval from the plan before the pharmacy can dispense certain medications. For Adderall-related prescriptions under Molina/Affinity plans, PA typically applies in these scenarios:

• Brand-name Adderall (when a generic equivalent exists)
• Adderall XR or generic extended-release mixed amphetamine salts (step therapy enforcement)
• Doses exceeding quantity limits (e.g., more than 60 tablets per 30 days for twice-daily dosing)
• Prescriptions for adults without documented prior ADHD diagnosis or evaluation

What Your Prescriber Needs to Submit

The PA request generally requires a confirmed DSM-5 ADHD diagnosis (codes F90.0, F90.1, F90.2, or F90.9), documentation of symptom severity, prior medication trials and outcomes, and the clinical rationale for the requested formulation [6]. Plans must respond to standard PA requests within 72 hours under New York State regulations. Urgent requests receive a 24-hour turnaround.

If Your PA Is Denied

A denial letter must include the specific clinical reason for the adverse determination and instructions for filing an appeal. Under New York law, you have 60 days to file an internal appeal. If the internal appeal is denied, you can request an external review through the New York State Department of Financial Services. During the appeal process, if you were already receiving the medication, you may be entitled to continuation of benefits pending the outcome.

Cost Expectations: What You Will Pay

Medicaid managed care copays in New York are among the lowest in the country. For preferred generic medications, the copay ranges from $0 to $3 per prescription, depending on the specific plan design [2].

Copay Breakdown by Formulation

| Formulation | Typical Tier | Estimated Copay | PA Required? | |---|---|---|---| | Generic mixed amphetamine salts IR | Preferred generic | $0 to $1 | No | | Generic mixed amphetamine salts XR | Non-preferred generic | $1 to $3 | Usually yes | | Brand Adderall | Non-preferred brand | $3+ | Yes | | Brand Adderall XR | Non-preferred brand | $3+ | Yes |

Federal law prohibits Medicaid programs from denying dispensing to members who cannot pay the copay at the pharmacy counter [7]. If you are below the federal poverty level or fall into certain exemption categories, your copay may be waived entirely.

Annual Out-of-Pocket Limits

New York Medicaid managed care plans impose an annual out-of-pocket maximum for prescription drugs. Once you hit that threshold, all subsequent prescriptions for the plan year carry no cost-sharing. The exact cap varies by plan, so check your member handbook or call the number on your Molina ID card.

ADHD Diagnosis Requirements for Coverage

No Medicaid managed care plan will cover Adderall without a documented ADHD diagnosis. The DSM-5 requires six or more symptoms of inattention and/or hyperactivity-impulsivity persisting for at least six months, with onset before age 12, symptoms present in two or more settings, and clear evidence that symptoms interfere with functioning [6].

Adult ADHD Evaluation

For adults seeking an initial ADHD diagnosis, plans may require a comprehensive evaluation that includes a clinical interview, validated rating scales such as the Adult ADHD Self-Report Scale (ASRS-v1.1), and collateral information. The World Health Organization developed the ASRS as a screening tool, and a 2005 validation study (N=154) found it had a sensitivity of 68.7% and specificity of 99.5% for identifying ADHD in adults [8].

Pediatric Prescribing Considerations

The AAP guideline recommends behavioral therapy as first-line treatment for children aged 4 to 5, with stimulant medication added if behavioral interventions alone are insufficient. For children 6 and older, the guideline supports stimulant medication as first-line, used alone or combined with behavioral therapy [5]. Medicaid managed care plans generally follow these age-based recommendations when evaluating PA requests.

Alternatives If Adderall Is Not Covered or Denied

If your Adderall prescription is denied or you prefer a different option, several alternatives exist on most Medicaid formularies.

Other Preferred Stimulants

Generic methylphenidate IR is almost universally a preferred drug on New York Medicaid formularies. A 2018 Cochrane review of 38 studies (N=5,111) comparing amphetamines to methylphenidate in adults with ADHD found no statistically significant difference in efficacy between the two drug classes, though individual response varies [9]. Your prescriber can switch to methylphenidate without prior authorization in most cases.

Non-Stimulant Options

Atomoxetine (generic Strattera) is a selective norepinephrine reuptake inhibitor approved for ADHD in children, adolescents, and adults. It does not carry the Schedule II controlled substance classification that applies to Adderall. A meta-analysis published in The Lancet Psychiatry (2018) examining 133 randomized controlled trials (N=24,177) found that amphetamines were more effective than atomoxetine for adult ADHD, but atomoxetine remained superior to placebo [10].

Guanfacine extended-release (generic Intuniv) and clonidine extended-release (generic Kapvay) are alpha-2 adrenergic agonists approved as adjunctive therapy or monotherapy for pediatric ADHD. These are useful when stimulants are contraindicated or produce unacceptable side effects such as significant appetite suppression or insomnia.

Manufacturer Assistance Programs

Teva Pharmaceuticals and other generic manufacturers do not typically offer patient assistance programs for generic mixed amphetamine salts because the cost is already low. Brand-name Adderall XR, manufactured by Teva (formerly Shire), has had copay assistance programs for commercially insured patients, but these programs generally exclude Medicaid beneficiaries by federal regulation.

How to Verify Your Specific Coverage

The most reliable way to confirm your Adderall coverage is to check directly with your plan. Three approaches work:

1. Call Member Services

The phone number on the back of your Molina Healthcare ID card connects you to a representative who can look up the formulary status of any medication in real time. Ask specifically: "Is generic mixed amphetamine salts immediate-release on the preferred drug list for my plan?"

2. Check the Online Formulary

Molina Healthcare publishes its formulary documents on its website. Look for the New York Medicaid Preferred Drug List. The document is organized by therapeutic class. ADHD stimulants appear under "Central Nervous System Agents" or "ADHD/Narcolepsy" depending on the version.

3. Ask Your Pharmacist

Your pharmacist can run a test claim through the system to determine whether your plan will pay for a specific drug, strength, and quantity before the prescriber writes the prescription. This real-time eligibility check reveals your exact copay and any PA requirements.

Filing a Complaint or Grievance

If you believe your plan has wrongly denied coverage for Adderall, you have several options beyond the standard appeal process. The New York State Department of Health oversees Medicaid managed care plans and accepts complaints from members who feel they have been denied medically necessary services [11]. You can also contact the New York State Office of the Medicaid Inspector General if you suspect fraud or abuse in the coverage determination process.

The Centers for Medicare and Medicaid Services (CMS) requires all Medicaid managed care organizations to maintain a grievance and appeal system that meets federal minimum standards, including specific timelines for acknowledgment, review, and resolution [7]. Document every interaction with your plan, including the date, representative name, and reference number for each call.

Controlled Substance Prescribing Rules in New York

Adderall is a Schedule II controlled substance under the federal Controlled Substances Act. New York adds additional prescribing requirements through its Internet System for Tracking Over-Prescribing (I-STOP) program, which mandates that prescribers check the Prescription Drug Monitoring Program (PDMP) database before writing a Schedule II prescription [12].

Prescription Validity and Refill Rules

Schedule II prescriptions cannot be called in to a pharmacy except in emergencies. In New York, electronic prescribing (EPCS) is mandatory for controlled substances. Each prescription is valid for 30 days from the date written. No refills are permitted on Schedule II medications, so your prescriber must issue a new prescription each month [12].

Quantity Limits

Most Medicaid managed care plans, including Molina/Affinity, impose quantity limits on Schedule II stimulants. A typical limit is 30 units per 30 days for once-daily formulations and 60 units per 30 days for twice-daily dosing. Quantities exceeding these limits require prior authorization with documented clinical justification.